US judge lets Eli Lilly (LLY) continue weight-loss drug ads, ruling against Novo Nordisk (NOVOB DC)

US judge lets Eli Lilly (LLY) continue weight-loss drug ads, ruling against Novo Nordisk (NOVOB DC)

Inter-company litigation over drug advertising claims sits in a familiar corner of pharma disputes: one sponsor alleging a rival's promotion is misleading, typically over comparative efficacy or safety framing in direct-to-consumer campaigns. Rulings of this kind rarely decide the commercial contest; they preserve or remove a marketing tool, and the revenue question is whether the challenged ads were actually moving prescribing. In the GLP-1 duopoly, share has historically tracked supply capacity, label breadth, and payer coverage far more than courtroom skirmishes, so the read-through to earnings has tended to be second order unless the ruling forces label or claims changes that alter how the drug can be positioned. The distinction worth drawing is between an injunction that halts a campaign outright and one that merely declines to, as here: the status quo holding means Lilly's messaging continues while the underlying dispute proceeds. Follow-ons are any appeal, parallel complaints at the advertising self-regulation bodies or the FDA's promotion arm, and whether the language of the ruling touches the comparative claims themselves rather than just the procedural posture.